Review article · 2025 · Open access

Akkermansia muciniphila: A key player in gut microbiota-based disease modulation

Nida Shaheen, Waleed Khursheed, Bijay Gurung, Shaohua Wang

Microbiological Research, 301, 128317 · Published 19 August 2025 · DOI 10.1016/j.micres.2025.128317

Open full textCite this paper

In brief

“Akkermansia muciniphila: A key player in gut microbiota-based disease modulation” is a 2025 review article by Nida Shaheen and 3 co-authors, published in Microbiological Research. OpenAlex counts 115 citations as of 21 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at Microbiological Research.

Citations
115
Most cited in
2026 (101)
Field-weighted impact
7.55
References
147
Authors
4

Abstract

Akkermansia muciniphila (A. muciniphila), a mucin-degrading bacterium residing in the gut's mucus layer, has emerged as a key modulator of host physiology with significant implications for health and disease. Growing evidence shows that A. muciniphila influences host metabolism, strengthens gut barrier integrity, modulates microbial composition, and regulates immune responses. This review synthesizes current literature on A. muciniphila, emphasizing its role in conditions such as metabolic disorders, inflammatory bowel disease (IBD), Clostridioides difficile infection (CDI), cancer, cardiovascular disease, and aging. In metabolic disorders, A. muciniphila improves insulin sensitivity, reduces adiposity, and increases GLP-1 secretion through mechanisms involving short-chain fatty acid (SCFA) production and TLR2 activation. It also restores microbial balance and reduces inflammation in type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). In IBD, it enhances mucus secretion, tight junction integrity, regulatory T cell expansion, and suppresses pro-inflammatory cytokines. In CDI, it promotes epithelial protection and colonization resistance by enriching butyrate producers. In cancer, it boosts immune checkpoint inhibitor efficacy by enhancing IL-12 and T cell activation. It also reduces vascular inflammation and calcification in cardiovascular disease via propionate production. In aging, A. muciniphila improves metabolic health, reduces chronic inflammation, promotes SCFA production, and preserves blood-brain barrier integrity. Both live and pasteurized forms are effective, with pasteurized, particularly Amuc_1100, showing enhanced benefits. Broader application requires large-scale trials, better understanding of host and strain variability, and development of personalized, synergistic therapies.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Shaheen, N., Khursheed, W., Gurung, B., & Wang, S. (2025). Akkermansia muciniphila: A key player in gut microbiota-based disease modulation. Microbiological Research, 301, 128317. https://doi.org/10.1016/j.micres.2025.128317

MLA 9

Shaheen, Nida, et al. “Akkermansia muciniphila: A key player in gut microbiota-based disease modulation.” Microbiological Research, vol. 301, 2025, p. 128317. https://doi.org/10.1016/j.micres.2025.128317.

Chicago

Shaheen, Nida, Waleed Khursheed, Bijay Gurung, and Shaohua Wang. 2025. “Akkermansia muciniphila: A key player in gut microbiota-based disease modulation.” Microbiological Research 301: 128317. https://doi.org/10.1016/j.micres.2025.128317.

Harvard

Shaheen, N. et al. (2025) ‘Akkermansia muciniphila: A key player in gut microbiota-based disease modulation’, Microbiological Research, 301, p. 128317. doi:10.1016/j.micres.2025.128317.

IEEE

N. Shaheen, W. Khursheed, B. Gurung, and S. Wang, “Akkermansia muciniphila: A key player in gut microbiota-based disease modulation,” Microbiological Research, vol. 301, p. 128317, 2025, doi: 10.1016/j.micres.2025.128317.

BibTeX

@article{shaheen2025akkermansia,
  title     = {{Akkermansia muciniphila: A key player in gut microbiota-based disease modulation}},
  author    = {Shaheen, Nida and Khursheed, Waleed and Gurung, Bijay and Wang, Shaohua},
  journal   = {Microbiological Research},
  year      = {2025},
  volume    = {301},
  pages     = {128317},
  doi       = {10.1016/j.micres.2025.128317},
  url       = {https://doi.org/10.1016/j.micres.2025.128317}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health

  • Akkermansia muciniphila
  • gut microbiota
  • mucin degradation
  • short-chain fatty acids
  • TLR2
  • insulin sensitivity
  • adiposity
  • glucagon-like peptide-1

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Shaheen, N., Khursheed, W., Gurung, B., & Wang, S. (2025). Akkermansia muciniphila: A key player in gut microbiota-based disease modulation. Microbiological Research, 301, 128317. https://doi.org/10.1016/j.micres.2025.128317

How many times has this paper been cited?

115 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Microbiological Research: sign in and open the full text from this page.

Who wrote this paper?

Nida Shaheen, Waleed Khursheed, Bijay Gurung, Shaohua Wang.

What is the DOI of this paper?

10.1016/j.micres.2025.128317, permanently at https://doi.org/10.1016/j.micres.2025.128317. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.